Pricing in some performance moderation
17/08/22 -"Considering the downward revision to the full-year outlook (in reported terms), due to external challenges like tougher FX, high inflation and supply chain challenges, we have revised downwards our ..."
Pages
49
Language
English
Published on
17/08/22
You may also be interested by these reports :
13/05/24
DiaSorin started 2024 on a promising note with sales and profitability exceeding expectations. Healthy growth across segments was offset by waning ...
10/05/24
While the 2023 EPS benefitted from material deferred tax income, we have moderated our earnings estimates for 2024-25 owing to high interest rates ...
10/05/24
Fresenius reported Q1 figures that exceeded the consensus, with revenues increasing by 0.3%, adjusted EBIT by 4.5%, net income from continuing ...
09/05/24
Smith & Nephew reported marginally softer than expected Q1 24 numbers. The weakness was largely attributable to US implants and areas within wound ...